Discovery
Optimisation
Pre-clinical
Phase 1
Phase 2
Small molecule, peptide, New Chemical Entity (NCE);
Primary indication: Ovarian Cancer;
Under evaluation from Kalos Therapeutics;
Published research: A novel, small peptide with activity against human pancreatic cancer. Michael R Kozlowski, Roni E Kozlowski (2020) Am J Cancer Res 2020;10(5):1356-1365